GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

but the concern that the drug might was sufficient to get it removed from the market. An over-the-counter medication sold today as Zantac 360 by Sanofi has a different active ingredient from the ...

GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK said late Wednesday that it agreed to settle a vast majority of lawsuits concerning its discontinued heartburn medicine Zantac. "GSK Shares Climb on $2.2 Bln Zantac Lawsuit Settlement," at 0754 ...

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market. The agency ...

"The settlement of $2.2 billion is lower than market expectations of $3.5 billion, and the announcement came sooner than expected. The Zantac clouds are lifting, and GSK will likely resolve the ...